Predictors of Short-Term Diabetes Remission After Laparoscopic Roux-en-Y Gastric Bypass
Gianluca Iacobellis, Cong Xu, Rene Campo, Nestor de la Cruz-Muñoz
- This study helps answer whether gastric bypass will cure a patient's diabetes by identifying which patients are most likely to achieve remission.
- Patients with shorter diabetes duration, lower preoperative A1c, and preserved beta-cell function had the highest likelihood of remission, meaning earlier surgery produces better chances of remission.
- This aligns with current diabetes care standards recommending metabolic surgery earlier, before years of insulin dependence.
- The study was a collaboration between Dr. de la Cruz-Muñoz and an endocrinologist, reflecting a team-based approach to metabolic surgery.
- Gastric bypass achieves diabetes remission in about 60-80% of patients at 2 years, with sustained remission in 30-50% at 10-15 years.
- For patients in Miami with diabetes and obesity, this study provides personalized, evidence-based guidance.
This study published in Obesity Surgery examined the preoperative clinical and metabolic factors that predict short-term type 2 diabetes remission following laparoscopic Roux-en-Y gastric bypass. The study analyzed a cohort of patients with T2DM, evaluating preoperative variables including diabetes duration, A1c levels, fasting glucose, insulin use, and beta-cell function to determine which factors independently predicted diabetes remission. Results identified shorter diabetes duration, lower preoperative A1c, and preserved beta-cell function as key predictors. Dr. de la Cruz-Muñoz is the senior and corresponding author.
Iacobellis G, Xu C, Campo R, De La Cruz-Muñoz N. Predictors of Short-Term Diabetes Remission After Laparoscopic Roux-en-Y Gastric Bypass. Obesity Surgery. 2015;25(5):782-787. doi:10.1007/s11695-014-1477-6.
